Business Wire
13 Jun 2026, 10:00 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
Incyte's frontMIND trial of the Tafasitamab combination showed prolonged progression-free survival (PFS). — Positive clinical trial results for a key drug candidate typically drive stock price appreciation and increase the likelihood of regulatory approval.
+0.60Which stocks this story touches
Positive trial results showing prolonged progression free survival for Tafasitamab combination.
Continue reading
6 related stories
Top 2 movers · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
7h ago
